Two Sigma Advisers’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-18,448
| Closed | -$625K | – | 1662 |
|
|
2025
Q4 | $625K | Buy |
+18,448
| New | +$573K | ﹤0.01% | 1693 |
|
|
2025
Q3 | – | Sell |
-23,673
| Closed | -$189K | – | 2581 |
|
|
2025
Q2 | $189K | Sell |
23,673
-17,065
| -42% | -$130K | ﹤0.01% | 2129 |
|
|
2025
Q1 | $398K | Sell |
40,738
-22,225
| -35% | -$219K | ﹤0.01% | 1879 |
|
|
2024
Q4 | $796K | Sell |
62,963
-25,162
| -29% | -$320K | ﹤0.01% | 1567 |
|
|
2024
Q3 | $1.42M | Buy |
88,125
+825
| +0.9% | +$16.7K | ﹤0.01% | 1250 |
|
|
2024
Q2 | $2.13M | Buy |
87,300
+44,487
| +104% | +$2.05M | ﹤0.01% | 1155 |
|
|
2024
Q1 | $3.08M | Buy |
42,813
+34,813
| +435% | +$4.84M | 0.01% | 994 |
|
|
2023
Q4 | $1.59M | Buy |
8,000
+612
| +8% | +$75.8K | ﹤0.01% | 1411 |
|
|
2023
Q3 | $982K | Sell |
7,388
-6,200
| -46% | -$1.01M | ﹤0.01% | 1530 |
|
|
2023
Q2 | $2.03M | Sell |
13,588
-1,275
| -9% | -$199K | 0.01% | 1192 |
|
|
2023
Q1 | $2.18M | Sell |
14,863
-2,300
| -13% | -$465K | 0.01% | 1233 |
|
|
2022
Q4 | $2.72M | Buy |
17,163
+75
| +0.4% | +$12K | 0.01% | 1068 |
|
|
2022
Q3 | $3.29M | Sell |
17,088
-5,700
| -25% | -$1.08M | 0.01% | 938 |
|
|
2022
Q2 | $3.33M | Sell |
22,788
-2,312
| -9% | -$308K | 0.01% | 952 |
|
|
2022
Q1 | $4.42M | Sell |
25,100
-3,375
| -12% | -$637K | 0.01% | 846 |
|
|
2021
Q4 | $8.37M | Sell |
28,475
-2,875
| -9% | -$768K | 0.02% | 563 |
|
|
2021
Q3 | $7.79M | Buy |
31,350
+16,025
| +105% | +$4.24M | 0.02% | 594 |
|
|
2021
Q2 | $3.9M | Buy |
15,325
+8,062
| +111% | +$1.51M | 0.01% | 974 |
|
|
2021
Q1 | $1.29M | Buy |
7,263
+3,213
| +79% | +$530K | ﹤0.01% | 1509 |
|
|
2020
Q4 | $640K | Buy |
4,050
+3,225
| +391% | +$701K | ﹤0.01% | 1772 |
|
|
2020
Q3 | $213K | Buy |
+825
| New | +$183K | ﹤0.01% | 2137 |
|
Two Sigma Advisers's RAPT Position: Q1 2026 in Review
Two Sigma Advisers sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 18,448 shares — an estimated $625K sold.
Two Sigma Advisers first reported a position in RAPT in Q3 2020 and held it in 21 quarters. The position peaked at $8.37M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Two Sigma Advisers reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 18,448 RAPT Therapeutics shares in Q1 2026, an estimated $625K.
- Two Sigma Advisers first reported a position in RAPT Therapeutics in Q3 2020 and held it in 21 quarters.
- Two Sigma Advisers's RAPT Therapeutics position peaked at $8.37M in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.